today show glp 1 Generic weight loss drugs to come off the market: What to know Starting a GLP-1? Listen to

The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course

Diverticulitis is a gastrointestinal condition characterized by inflamed or infected pouches in the digestive tract

Our private label GLP-1 Booster formula is strategically developed to allow partners to enter this high-growth category quickly, professionally, and with a clinically positioned product that resonates with modern weight-management consumers

“Millions of Americans could benefit from GLP-1s, but clinical trials suggest patients need to stay on these drugs to experience sustained benefits,&rdquo

Supporting beneficial bacteria may help promote digestive balance and metabolic wellness

Evaluate projects that GLP-1 obesity drugs, like Wegovy and Mounjaro, are set to drive record prescription drug sales growth by 2030.